Other research analysts have also recently issued research reports about the company. JPMorgan Chase & Co. raised Genmab A/S from a “neutral” rating to an “overweight” rating and set a $23.00 target price on the stock in a research report on Thursday, September 12th. HC Wainwright reissued a “buy” rating and issued a $25.00 price target on shares of Genmab A/S in a research report on Wednesday, November 20th. Guggenheim started coverage on Genmab A/S in a research note on Monday, August 12th. They set a “buy” rating on the stock. Royal Bank of Canada started coverage on shares of Genmab A/S in a report on Monday, August 12th. They set an “outperform” rating and a $23.00 price objective on the stock. Finally, Bank of America upgraded shares of Genmab A/S from a “neutral” rating to a “buy” rating in a research note on Friday, September 13th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Genmab A/S currently has a consensus rating of “Buy” and an average target price of $23.67.
Shares of Genmab A/S stock traded up $0.15 on Tuesday, hitting $23.80. The company had a trading volume of 229,386 shares, compared to its average volume of 196,161. Genmab A/S has a 1 year low of $14.48 and a 1 year high of $24.50. The company has a debt-to-equity ratio of 0.01, a current ratio of 18.72 and a quick ratio of 18.72. The stock’s 50 day simple moving average is $22.06. The firm has a market capitalization of $3.01 billion and a PE ratio of 6.33.
About Genmab A/S
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.